Article info

Download PDFPDF
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Authors

  1. Correspondence to Professor Daniel Aletaha, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria; daniel.aletaha{at}meduniwien.ac.at
View Full Text

Citation

Bonelli M, Mrak D, Tobudic S, et al
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Publication history

  • Received September 22, 2021
  • Accepted December 10, 2021
  • First published January 13, 2022.
Online issue publication 
April 08, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.